scPharmaceuticals Inc. (SCPH)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John H. Tucker | President, CEO, Principal Executive Officer & Director | 981.56k | -- | 1963 |
| Ms. Rachael Nokes | CFO & Principal Accounting Officer | 573.8k | -- | 1976 |
| Mr. Michael D. Hassman | Senior Vice President of Technical Operations | -- | -- | -- |
| Katherine Taudvin | Vice President of Corporate Affairs & Human Resources | -- | -- | -- |
| Dr. John Mohr Pharm.D. | Senior Vice President of Clinical Development & Medical Affairs | -- | -- | -- |
| Steve Parsons | Senior Vice President of Commercial | -- | -- | -- |
scPharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 135
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Corporate Governance
Recent Events
- Apr 12, 2024PRE 14A: Proxy StatementsSee Full Filing
- Apr 05, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Mar 20, 2024CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing
- Mar 13, 2024S-3: Offering RegistrationsSee Full Filing
- Jan 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing